Clinical investigation of antiarrhythmic devices. A statement for healthcare professionals from a joint task force of the North American Society of Pacing and Electrophysiology, the American College of Cardiology, the American Heart Association, and the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology

Implantable Cardioverter Defibrillator: Current Progress and Management

With greater technologic advances during the past decade, use of the implantable cardioverter defibrillator (ICD) has increased to more than 200,000 implants worldwide to date. Indications for ICD implant have expanded to include both patients who have survived sudden cardiac death (secondary prevention of cardiac arrest) and those who are at high risk for experiencing lethal arrhythmias (primary prevention of cardiac ar rest). Thus, it is likely that physicians will encounter defibrillators in their clinical practice and must be familiar with their indications for implant, basic opera tion, and long-term management of devices. Several prospective clinical trials have recently shown the long- term efficacy of ICD therapy at aborting sudden death in the high-risk patient population. Although still evolving, general guidelines and indications for ICD implant have been put forth and are discussed in this review. From the first defibrillation in humans during surgery in 1947 to the sophisticated dual-chamber pacing and memory functions of the modern device, ICD development has led to ever smaller devices with more complex technol ogy. The implant procedure of current ICDs parallels that used to place pacemakers. However, the anesthe sia team plays a vital role in initial ICD implantation by monitoring cardiopulmonary status during defibrilla tion threshold (DFT) testing. Additionally, long-term management of ICDs often requires repeat DFT testing with anesthesia involvement. Finally, possible electro magnetic (environmental) interactions with the ICD of which physicians should be aware are described in this article.

Effects of intracardiac radiofrequency current application on coronary artery vessels in young pigs

INTRODUCTION

Radiofrequency current is widely used in children to ablate accessory AV pathways. Previous data in a pig model demonstrated coronary artery obstruction adjacent to radiofrequency current lesions 48 hours and 6 months after energy delivery. In the present study, the long-term effects (>6 months) of radiofrequency current application on coronary artery vessels in young pigs are assessed.

METHODS AND RESULTS

Radiofrequency current (500 kHz) was delivered over 30 seconds in ten piglets (mean body weight 12.8 kg) using a steerable 6-French catheter with a 4-mm thermistor tip electrode (target temperature 75 degrees C). Lesions were created under fluoroscopic and electrocardiographic guidance at the lateral right atrial (RA) wall above the tricuspid valve orifice, and at the lateral left atrial and left ventricular wall adjacent to the mitral valve orifice. Selective coronary angiography and intravascular ultrasound (IVUS) studies were performed 3, 6, 9, and 12 months after energy application. After 12 months, the lesions were studied pathohistologically. All lesions consisted of compact fibrous tissue. RA lesions extended to the adjacent right coronary artery and led to coronary artery involvement with increased fibrous tissue in the adventitia and media and intimal thickening in three animals. Coronary arterial narrowing was documented by IVUS during follow-up in all three cases 9 months after energy application. Angiography failed to demonstrate coronary pathology in any of the three animals.

CONCLUSION

The risk of late coronary artery lesions must be considered when catheter ablation at the RA wall is planned in children with free-wall accessory AV pathways.

[Defibrillator therapy 1997. Prerequisites--results--prospects]

BACKGROUND

The first human cardioverter defibrillator implant was performed in 1980. Since then, significant technological improvement has been performed and today, ICDs with multiple diagnostic and therapeutic features are available. We report on 541 patients who underwent ICD implantation between January 1984 and March 1997. Epicardial ICD implant was performed in 209 patients (39%) and 332 patients (61%) received transvenous ICDs.

PATIENTS AND RESULTS

Perioperative mortality was 2% (13 patients), significantly more frequent after epicardial (12/209 patients, 6%) than after transvenous implantation (1/332 patients) (p < 0.01). During a mean follow-up of 28 +/- 23 months, 104 patients died (20%), 15 of them (3%) suddenly. 8407 arrhythmic episodes were observed and terminated by antitachycardia pacing in 6655 (79%). Infections occurred in 13 patients (2%), electrode complications in 43 patients (8%) and inappropriate shocks in 84 patients (16%).

CONCLUSION

The ICD is an effective approach to treat patients with life-threatening ventricular tachyarrhythmias leading to a low incidence of sudden death. Today, there is a low operative risk and modern ICDs have multiple diagnostic and therapeutic features that allow individual ICD therapy.